期刊文献+

肿瘤微环境响应型药物递送系统研究进展 被引量:1

Research progress in tumor microenvironment-responsive drug delivery system
下载PDF
导出
摘要 肿瘤微环境是一个极其复杂的内部微环境系统。一方面,复杂的肿瘤微环境对药物递送造成了障碍,极大地降低了药物递送系统的递送效率,为肿瘤的治疗带来了巨大阻碍;另一方面,研究者可针对其特定微环境设计特异微环境响应型药物递送系统,实现药物在肿瘤组织的靶向递送。本文综述了基于肿瘤微环境响应的可降解药物递送系统的设计,主要从肿瘤微环境的低pH、乏氧、高谷胱甘肽、高活性氧四个方面展开,为研究肿瘤的多模态治疗提供参考。 The tumor microenvironment is an extremely complex internal microenvironment system.On the one hand,the complex tumor microenvironment has caused obstacles to drug delivery,greatly reducing the efficiency of the drug delivery system in tumor treatment.On the other hand,we can design a specific microenvironment-responsive drug delivery system to achieve targeted delivery of drugs in tumor tissues.This article reviewed the design of the degradable drug delivery system based on the tumor microenvironment response from four aspects of the tumor microenvironment:low pH,hypoxia,high glutathione and high reactive oxygen,to provide methodological reference for research of multimodal treatment of cancer.
作者 杨锦昱 谢锦珊 白菁钰 周宏磊 程迪 朱维平 YANG Jin-yu;XIE Jin-shan;BAI Jing-yu;ZHOU Hong-lei;CHENG Di;ZHU Wei-ping(Department of Pharmaceutical Engineering,School of Pharmacy,East China University of Science and Technology,Shanghai 200237;Institute of Pesticide and Pharmaceuticals,School of Pharmacy,Shanghai Key Laboratory of Chemical Biology,East China University of Science and Technology,Shanghai 200237)
出处 《中南药学》 CAS 2021年第6期1219-1227,共9页 Central South Pharmacy
基金 华东理工大学大学生创新创业训练计划项目(No.X19101)。
关键词 肿瘤微环境 多模态治疗 药物递送系统 刺激响应 可降解 tumor microenvironment multimodal therapy drug delivery system stimulus response degradable
  • 相关文献

参考文献7

二级参考文献61

  • 1PINZANI V, BRESSOLLE F, HAUG I J, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review[J]. Cancer Chemother Pharmacol, 1994, 35(1): 1-9.
  • 2GOTTESMAN M M. Mechanisms of cancer drug resistance[J]. Annu Rev Med, 2002, 53: 615-627.
  • 3THOMAS H, COLEY H M. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein[J]. Cancer Control, 2003, 10(2): 159-165.
  • 4HUYNH N T, ROGER E, LAUTRAM N, et al. The rise and rise of stealth nanocarriers for cancer therapy: Passive versus active targeting[J]. Nanomedicine (Lond), 2010, 5(9): 1415-1433.
  • 5KEDAR U, PHUTANE P, SHIDHAYE S, et al. Advances in polymeric micelles for drug delivery and tumor targeting[J]. Nanomedicine, 2010, 6(6): 714-729.
  • 6CUKIERMAN E, KHAN D R. The benefits and challenges associated with the use of drug delivery systems in cancer therapy[J]. Biochem Pharmacol, 2010, 80(5): 762-770.
  • 7HALL M D, HANDLEY M D, GOTTESMAN M M. Is resistance useless? Multidrug resistance and collateral sensitivity[J]. Trends Pharmacol Sci, 2009, 30(10): 546-556.
  • 8LIN J H, YAMAZAKI M. Role of P-glycoprotein in pharmacokinetics: Clinical implications[J]. Clin Pharmacokinet, 2003, 42(1): 59-98.
  • 9KRISHNA R, MAYER L D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[J]. Eur J Pharm Sci, 2000, 11(4): 265-283.
  • 10LIU F, XIE Z H, CAI G P, et al. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells[J]. Biol Pharm Bull, 2007, 30(12): 2279-2283.

共引文献25

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部